Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib plus Capecitabine in Metastatic Breast Cancer
NCT00077363Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started May 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00077363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077363.